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Abstract: 
Purpose: With the increase of proton therapy centers, there is a growing need to make progress in 
preclinical proton radiation biology to give accessible data to medical physicists and practicing 
radiation oncologists.  
Methods: A cyclotron usually producing radio-isotopes with a proton beam at an energy of about 25 
MeV after acceleration, was used for radiobiology studies. Depleted silicon surface barrier detectors 
were used for the beam energy measurement. A complementary metal oxide semiconductor (CMOS) 
sensor and a plastic scintillator detector were used for fluence measurement, and compared to Geant4 
and an in-house analytical dose modeling developed for this purpose. Also, from the energy 
measurement of each attenuated beam, the dose-averaged linear energy transfer (LETd) was calculated 
with Geant4.   
Results:  The measured proton beam energy was 24.85 ± 0.14 MeV with an energy straggling of 127 
± 22 keV before scattering and extraction in air. The measured flatness was within ± 2.1 % over 9 mm 
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diameter. A wide range of LETd is achievable: constant between the entrance and the exit of the 
cancer cell sample ranging from 2.2 keV/µm to 8 keV/µm, beyond 20 keV/µm, and an average of 2-5 
keV/µm in a SOBP calculated for an example of a 6 mm-thick xenograft tumor. 
Conclusion: The dosimetry and the characterization of a 25 MeV proton beam line for pre-clinical 
radiobiology research was performed by measurements and modeling, demonstrating the feasibility of 
delivering a proton beam for preclinical in vivo and in vitro studies with LETd of clinical interest. 
 
Key words: proton beam, preclinical studies, small animal irradiation, in vitro irradiation  
 
I. INTRODUCTION 
Despite the high potential of proton therapy (PT), the clinical evidence supporting the broad use of 
protons is still under debate.1, 2 Reducing the dose to normal tissues and organs surrounding the target 
areas is the key feature of protons versus photons irradiation.3 However, does the advantage of proton 
dosimetry be reflected in significant gains for patients? Translation of this absorbed dose reduction 
into clinically relevant benefit has still not been consistently demonstrated.4 However, a semi-
personalized approach can be used based on the  linear energy transfer (LET) to reoptimize the 
treatment plan for intensity modulated PT.5 This method demonstrated a safer treatment by mitigating 
a potentially increased risk of side effects resulting from elevated relative biological effectiveness of 
proton beams near the end of the range.5 Recently, studies focused on predicting patient-specific 
dosimetric benefits of PT6 and dose escalation. For example, Liu et al. demonstrated that proton 
radiation dose escalation improved local control but also increased toxicity.7 However, the lack of 
identifying biomarkers for conclusive patients outcome, limits the transfer of PT into personalized 
medicine.  
Small-animal proton irradiations are required to contribute to overcome these issues. Most of 
experiments are performed with clinical energy protons (between 70 and 250 MeV) to mimic for 
example space radiation conditions,8 with whole body and/or whole brain irradiations. Although a 
clinical proton beam energy seems relevant for radiobiological studies, animals or cell samples are 
usually irradiated in the plateau of the Bragg curve with a LET of about 1.5 keV/µm, which is a 
typical LET found in patients normal tissues (beam entrance). However, Grassberger et al. 
demonstrated that single fields with various range in different patients lead to high LETd areas around 
8–12 keV/μm into pristine peaks (depending on beam energy) and of about 8 keV/μm for passive 
scattering spread-out Bragg peak (SOBP) fields.9 In intensity modulated proton therapy treatment 
plans, LETd values within the target (e.g. brain tumor) range from ≈1.5 to 4 keV/μm, depending on 
the optimization dose delivery technique used.9 Thus, radiobiologists focus on a wide range of LET to 
study different scenarios happening in patients. For instance, Ogata et al. irradiated human 
fibrosarcoma cells at 5 points along a 190 MeV proton beam with its Bragg peak modulated to 6 cm 
showing that proton irradiation suppresses metastatic potential.10 This common irradiation method is 
usually performed to obtain a broad range of LET despite the large uncertainties of LET values 
mostly near the Bragg peak. In a recent study, Prezado and colleagues demonstrated that 100 MeV 
proton minibeam, corresponding to an estimated LET of about 5 keV/µm at the entrance and 15 
keV/µm in the Bragg peak, minimized normal tissue damage in the rat brain compared to broad 
beam.11 In addition, several low energy proton platforms (of about 3 MeV corresponding to a LET ≈ 
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12 keV/µm at the entrance of the depth-dose curve) allow cell samples irradiation12 ranging from the 
single-cell scale13, 14 to in vivo skin irradiation.15 
Currently, proton preclinical platforms (E ≤ 50 MeV) are burgeoning, offering the technical precision 
required to deliver precise millimeter-sized beams to localized regions within rodents.16–18 Small-
animal radiotherapy research platforms mimicking accurately human radiotherapy conditions are 
needed to reproduce pathologies observed in patients (improvement of animal models) and better 
understand the therapeutic possibilities and toxicities of PT. Several studies already improved the 
beam delivery and dose calculation for focal irradiation in the rat brain with gamma-rays19 and image-
guided X-rays.20, 21 Also, recent improvement in preclinical radiotherapy research have stimulated the 
development of dedicated X-rays irradiators for small animals such as mice and rats.22–24  
This article presents the development of a proton beam platform dedicated to in vivo and in vitro 
radiobiological studies, using the 25 MeV cyclotron CYRCé (IPHC) as a proton source. A dedicated 
treatment planning system (analytical calculation) is used to deliver the absorbed dose to small 
animals and cells,25 and the beam energy and fluence are characterized. Based on the energy 
measurement and calculation, and a beam energy degrader wheel, leading to a broad range of LETd, 
this platform is demonstrating the feasibility of radiobiological studies of clinical interest.  
 
II. MATERIALS AND METHODS 
II.A. Experimental set-up 
The experimental set-up is illustrated in Figure 1. The proton beam is extracted from the CYRCé 
cyclotron (TR24, ACSI, Canada), used initially for the production of radio-isotopes, with an extracted 
beam energy of about 25 MeV after acceleration. To reach the beam stability (in a range of a 
corresponding dose rate of 2Gy/ min) with an intensity fluctuation less than 1% over 1 to 10 minutes 
irradiation duration, the beam current was set to obtain 200 fA to 30 pA at sample position. The 
irradiation duration was controlled with a beam kicker located between the source and the entrance of 
the cyclotron acceleration cavity (30 keV ion beam) to allow a fast beam shut off. The output beam 
passes through a switching magnet followed by a beam pipe where the protons are centered with a 5 
mm collimator. A homogeneous broad beam is obtained with a movable Al-scattering foil (200 µm 
thick) set behind the 5 mm collimator 240 cm upstream from the end of the beam line, where an exit 
window is made of 50 µm thick aluminum. An energy degrader is located three centimeters 
downstream this exit window (Fig. 1). The energy degrader consists on Al thicknesses ranging from 
147 µm to 2761 µm, allowing LET variation and SOBP delivery (see section II.E). The final 
transverse shape of the proton beam is managed by a 10 mm thick aluminum collimator located after 
the degrader. 
In addition to being mechanically centered inside the vacuum pipe, the proton beam is horizontally 
centered (no vertical control centering) using the switching magnet before each irradiation procedure. 
The beam centering is controlled by a beam profiler, which is made of 0.5 mm-thick tungsten blade 
placed on a (X, Y) automated movable system (travel range of 41 mm, precision < 1 nm). The 
profiler, connected to a Keithley picoammeter (6487, Tektronix), measures the beam current by 
collecting proton charges from beam interacting with the tungsten blade. The beam is scanned in steps 
of 0.5 mm and lead to a 1D Gaussian profile. To control the beam current, a movable Faraday cup is 
set at the end of the beam line. 
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The extracted proton beam energy and the energy straggling in air was measured behind the 
collimator. For this measurement, four stacked depleted Silicon Surface Barrier Detectors (SSBD) 
(ORTEC B-018-150 and A-019-150) were used (Fig. 2), with a sensitive depth of 252 µm, 1007 µm, 
2022 µm and 3000 µm respectively.  
Each SSBD was firstly calibrated in vacuum chamber with a tri-alpha source of 239Pu, 241Am, 244Cm, 
emitting particles of 5.805, 5.486 and 5.155 MeV respectively. Since the energy of the beam to be 
measured is of the order of 25 MeV, using only this low energy calibration would lead to an important 
error for large energy deposits. An iterative self-calibration method was then used. 
For this measurement, the maximum energy achievable by the cyclotron has been fixed. The energy 
loss and the residual energy in each detector were then measured for different beam energies using the 
energy degrader whose aluminum thicknesses are known (9 positions was used to vary the beam 
energy between approximately 25 to 10 MeV). The energy loss in the degrader and therefore the 
energy deposited in each detection stage depend on the beam initial energy. 
Then, a self-calibration method is performed consisting in the variation of the theoretical energy of 
the initial beam around its theoretical energy (25 MeV) and calculating for each position of the 
degrader the energy loss in the Al foil as well as the energy then expected in each detection stage. It 
was then compared to its theoretical value given by an analytical algorithm (see section II.E), which 
calculates the outgoing proton energy using the PSTAR stopping power database. The real energy of 
the measured beam is then obtained when for all 4 detectors the calculated points are aligned with 
the experimental data as well as with the points measured with the 3-alpha source. 
From this method, the initial energy of the proton beam was found E0 = (24.85 ± 0.14) MeV with an 
energy straggling σE = (127 ± 22) keV. The energy uncertainty was obtained by means of residuals on 
the calibration curve, and the energy straggling uncertainty was obtained by unfolding the silicon 
detectors resolution and accounting for the impact of the proton beam scattered by the two 200 µm-
thick and 50 µm-thick Al foils (most significant contributions). The energy straggling assessment was 
previously described by Vanstalle et al.25 
Finally, the platform offers both in vitro and in vivo irradiations. For example, tumor xenograft 
located in mice hind paws can be irradiated directly in contact with the collimator, using an in-house 
immobilization bed (Fig. 3a). To date, cells can be irradiated into 24, 48 and 96 well plates 
(depending on the collimator size used) in a dedicated automated (X, Y) sample holder (Fig. 3b). For 
instance, the diameter of the bottom well (where cells grow) of a 48 well plate is 9.8 mm (Multiwell 
TC plates, Corning Life Sciences), with a center-to-center distance of 12.9 mm. Therefore with a 10 
mm diameter collimator and a precise automated displacement (X, Y translation tables precise at 100 
µm), we can obtain uniform irradiation over the cell layer. 
 
II.B. Fluence measurements 
It is noteworthy that no standard protocol is available for preclinical proton beam commissioning with 
energies below 30 MeV. Indeed, due to a sub-centimeter penetration depth in water, ionization 
chambers cannot be easily used in a standard water phantom, and the measurement of the percentage 
depth-dose remain challenging due to the proton energy that is about 3 MeV in the Bragg peak, 
corresponding to approximately 160 µm range in water. 
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A plastic scintillator detector and a CMOS sensor used for fluence measurements were positioned 
behind a 10 mm diameter collimator (40 mm downstream of the exit window) and exposed to the 
proton beam perpendicularly incident. Briefly, a water-equivalent plastic scintillator detector of 25 × 
25 × 10 mm3 (BC-420, Saint-Gobain, Newbury, OH, USA) was placed downstream of the collimators 
to count the number of protons (related to beam current) at the irradiation position and compared to 
the beam current measured by the Faraday cup. It worth to mentioned that these to measurements 
cannot be performed simultaneously. When the correlation between the plastic scintillator and the 
cup is obtained, the plastic scintillator is removed and the beam flux is set only with the Faraday 
cup.26 The CMOS sensor MIMOSA28 was characterized in a previous study26 for fluence 
measurement (total number of particles collected per cm²) with the set-up described in section II.A. 
The CMOS chip has a sensitive area of about 2×2 cm² and consists of an array of 928 lines and 960 
columns of pixels with 20.7 microns pitch. The total thickness of the sensor is 50 µm, including the 
sensitive epitaxial layer of 14 µm-thick silicon, with a spatial resolution below 10 µm.27 The detection 
efficiency of this sensor is 99.5% for the relevant range of proton energies in our beam, since it was 
optimized for minimum ionizing particles in high energy particle experiments.28–30 
 
II.C. Geant4 simulation 
To compare calculation with the measured beam profiles, Monte Carlo simulations were performed 
with Geant4 10.03,31 using the binary light ion cascade (BIC) to model proton interactions.32 The BIC 
model, called G4BinaryLightIonReaction, is an extension of the binary cascade model. The pre-
defined physics list was QGSP_BIC, modeling proton interactions along its path, including the Au 
scattering foil, the Al collimator and extraction foil (interface vacuum-air) at the end of the beam 
line, and secondary particles. Also, for LET calculations simulating biological experiment conditions, 
the water equivalent thickness of the petri dish and the energy straggling were taken into account. 
In this model, the participating particles, i.e. primary particles or particles generated during the 
cascade process, are described by means of Gaussian wave functions. Also, a range cut of 1 mm and 
a step size of 0.1 mm were applied, which is sufficiently small as demonstrated in several studies.33–
35 
II.D. Dose-averaged LET calculation 
The LET is usually averaged over a target volume and an energy spectrum of a specified 
type of charged particles. In this study, we used the dose-averaged LET (LETd),9, 36 including 
both the dose and the original definition of the LET. LETd distributions are generated by 
scoring each energy deposition in the medium. At each energy deposition associated with a 
particle energy loss (dE), the length of the particle step (dx) was obtained. All values were 
scored voxel by voxel (v) and as dose-to-tissue to calculate the LETd in MeV/g cm²: 
ܮܧ ௗܶ(ݒ) =
∑ ݀ܧ ∙ (݀ܧ ݀ݔ⁄ ) 1ߩ௘௩௘௡௧௦
∑ ݀ܧ௘௩௘௡௧௦ 	(1) 
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The electronic stopping power (݀ܧ ݀ݔ⁄ ) is used in the calculation (PSTAR database), which 
implies that LET is calculated without the production of delta electrons. Also, the nuclear 
stopping power is neglected and ρ is the mass density of the current medium (here, water) 
where proton energy is deposited.  
II.E. Calculation of the absorbed dose 
An analytical algorithm, referred to as PSD function, was developed to define the weight of each 
Bragg peak composing the SOBP delivery in small animal tumors.25 It is noteworthy that the PSD 
function is valid for low energy protons (below 50 MeV) and applicable for various geometry and size 
of tumors, but in this study, an example of a 6 mm thick xenograft tumors will be considered. It 
consists in a calculation based on Bortfeld et al.37 using the proton range extrapolated from the 
PSTAR database.38 The PSD function implements the range straggling σR, and the influence of 
aluminum thicknesses (energy degrader) on the transmitted proton beam. Indeed, proton beam fluence 
decreases due to nuclear reactions between incident protons and the target. Also, to reproduce the 
beam propagation in the target, a multiple scattering calculation was used. Using the PSD function, 
the irradiation duration to deliver the right number of protons for each proton beam energy to cell 
samples and composing the SOBP is set to deliver the proper dose into the target volume.  
III. RESULTS 
III.A. Beam characterization 
The 2D beam fluence was assessed with the CMOS sensor located behind the 10 mm collimator with 
a fluence fixed at approximately 6.7×107 cm-2 (corresponding to ≈ 25 cGy) in the plateau region of the 
beam path (Fig. 4, left panel) at maximum energy (24.85 MeV). After extraction in air the beam 
energy entering the CMOS sensor was 23.52 ± 0.15 MeV (30 mm from the exit window). The beam 
lateral profiles were assessed with the CMOS sensor and compared to Geant4 calculation and the PSD 
function (Fig. 4, right panel). The lateral profiles were flat in the central region, then fall off rapidly in 
the penumbral region. Spatial heterogeneities obtained with the CMOS sensor were: ± 1.8% on the X-
axis (cyan line) and ± 2.1% on the Y-axis (cyan dots) over a circular region of 9 mm diameter. A 
slight increase on the right edge of the Y profile can be observed and is due to a misalignment of the 
beam since no vertical control centering is available to date. The full width at half maximum of lateral 
profiles were in agreement within a distance of 0.1 mm between the CMOS sensor, Geant4 
simulations and the PSD function, demonstrating the validity of the in-house lateral scattering 
calculation of the proton beam. 
In routine irradiation procedures, the beam current in air ܫ௔௜௥  (expressed in Ampere) is calculated 
from the beam current measured by the Faraday cup. Then, the irradiation time tirr (precision < 190 
µs) can be determined according to Eq. 112 to obtain a theoretical absorbed dose D into the 
scintillator detector (corresponding to biological samples position). This is done by accounting for 
the LETd of 23.52 MeV protons in water (2.2 keV/µm) in the region of the plateau of the Bragg curve: 
ݐ௜௥௥ = ஽ଵ.଺×ଵ଴షవ×௅ா்೏×൤಺ೌ೔ೝ	೜೛ ×భಲ൨
	  (2) 
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where, ݍ௣ is the proton charge, and A is the area of the collimator (cm²). Overall, the relative 
uncertainty of the absorbed dose can be assessed based on (2): 
∆஽
஽ = ට(
∆௧೔ೝೝ
௧೔ೝೝ )ଶ + (
∆௅ா்೏
௅ா்೏ )ଶ + (
∆ூೌ೔ೝ
ூೌ೔ೝ )ଶ + (
∆஺
஺ )ଶ    (3) 
with, ∆ݐ௜௥௥ ݐ௜௥௥⁄  negligible,	∆ܣ ܣ⁄  negligible since the collimator size is (2 ± 0.01) cm, ∆ܮܧܶ ܮܧܶ⁄  < ± 
5% (given by PSTAR database) and ∆ܫ௔௜௥ ܫ௔௜௥⁄  < ± 1% (the plastic scintillator measurement set-up 
processes up to 700 000 protons per second). Therefore, the relative uncertainty on the absorbed 
dose is of about ± 5% with a beam uniformity of ± 2% over 2 cm diameter irradiation. 
III.B. Experimental verification of the fluence based on the analytical algorithm: a specific 
example 
The PSD function was used to calculate the SOBP corresponding to an absorbed dose of 1 Gy in a 6 
mm xenograft tumor volume with energy modulation (18 Al-thicknesses) (Fig. 5, left panel).  
On the right panel of Figure 5, the difference in number of protons between measurements and the 
PSD function at the entrance of the water-equivalent depth (corresponding to the Bragg peak with the 
lowest weight) represents a deviation < 0.1% over the total absorbed dose, which is negligible 
considering its contribution in the SOBP calculation (low weighting factor).  
 
III.C. Dose-averaged LET Range 
The proton dose-averaged LET range versus the penetration depth in water was calculated with 
Geant4 (Fig. 6, left panel) for different proton energies. For cell irradiation (zoom-in region in Fig. 6), 
growing on a 2 mm thick petri dish (or flask), the proton beam energy can be degraded ranging from 
23 MeV (LETd = 2.8 keV/µm) to 15 MeV (LETd ≈ 7 keV/µm), obtaining a constant LETd (within 5%) 
across the cell nucleus (10 µm) growing in a monolayer culture. In addition, for in vivo experiments 
with for example a xenograft tumor of 6 mm (as described in section III.B) irradiated with a total 
absorbed dose of 1 Gy, the LETd is about 2-5 keV/µm with a maximum of 40 keV/µm in the pristine 
Bragg peak composing the SOBP (Fig. 6, right panel). 
 
Discussion 
With the increase of proton therapy centers there is a growing need to make progress in proton 
radiation biology to give accessible data to practicing radiation oncologists. The measurements and 
modeling results presented here demonstrate the feasibility of delivering a proton beam for preclinical 
in vivo and in vitro studies with LETd of clinical interest. With the low energy straggling and lateral 
scattering of the beam, this proton preclinical platform offers the technical precision required to 
deliver a uniform beam to localized regions within a small animal and in vitro studies. The nominal 
energy of the beam is E0 = (24.85 ± 0.14) MeV with an energy straggling σE = (127 ± 22) keV, the 
beam flatness is better than ± 2.1%, and the absorbed dose is estimated better than ± 5%. Moreover, 
using the degrader wheel, the energy is well known and controlled, guaranteeing robust LETd values. 
Also, this system produces an SOBP at a maximum depth that is useful for small animal tumor 
models within 6 mm depth.  
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Because of a lack of biological input parameters, the ability to predict relative biological effectiveness 
(RBE) for all tissues in treatment planning is limited, and thus the use of a generic RBE of 1.1 was 
recommended.39 However, in the Bragg peak area, the average proton energy decreases rapidly, 
leading to an increase of the LET values that influences (amongst others parameters such as dose, 
fractionation, tissue, and biological endpoint) the RBE of protons. Consequently, there is RBE-based 
heterogeneity throughout the target and adjacent normal structures.40 As discussed by Unkelbach et 
al.,5 this is an issue for proton therapy planning, especially for intensity modulated proton therapy, 
which may deliver highly inhomogeneous LET distributions, even for homogeneous physical dose 
distributions. This may result in LET hot spots in critical structures within or near the target volume, 
with LET values higher than those observed for passive scattering for instance. Although it might be 
difficult to incorporate all parameters influencing RBE, biologically motivated treatment planning 
could at least be guided by LETd, as suggested by Grassberger et al.9 Thus, it might be feasible to 
incorporate physics-related RBE effects using a single physics parameter, the LETd. With a constant 
LETd values between the entrance and the exit of the cell sample ranging from 2.2 keV/µm to 8 
keV/µm, higher LETd beyond 20 keV/µm, and an average LETd of 2-3 keV/µm in a SOBP delivered 
to a xenograft tumor (for example), LETd-dependent biological effects may be observable with this 
proton beam platform. A final challenge will be to experimentally determine the LETd for the range of 
energies instead of using only Monte Carlo and PSTAR database. With carefully designed in vivo and 
in vitro experiments it may be possible to explore a wide range of LETd response and implement these 
radiobiological results in clinical treatment planning system. 
Several proton irradiation platform were specifically designed for radiobiology research. For example, 
Greubel et al. adapted a tandem 14 MV van de Graaff accelerator to accelerate protons up to 25 MeV. 
It has been used to study the response of a head-and-neck squamous cell carcinoma cell line to proton 
irradiation using a flank xenograft model16 and the response of skin41 to proton microbeams with high 
dose rates. A limitation of these studies, as well as our, is the lack of the percentage depth-dose 
measurement. We measured the lateral fluence of the beam with the CMOS sensor26 compared to 
Geant4 and PSD function calculation, demonstrating an excellent homogeneity and flatness, however, 
the integral depth dose measurement in water of the 10 mm collimated proton beam at 23.5 MeV 
would have been required to fully characterize the proton beam and the validity of the in-house 
treatment plan.25 The percentage depth-dose will be measured in a future study. Nevertheless, the 
nominal proton beam energy was appropriately assessed as well as each energy downstream Al-
thicknesses attenuator.  
Conclusions 
The fluence and energy characterization, the in-house and Geant4 modeling demonstrate the 
feasibility of using an existing cyclotron system to deliver a proton beam that is suitable for 
radiobiology studies with the possibility to explore a wide range of dose-averaged LET. 
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Figure captions: 
Fig. 1. Schematic view of the horizontal beam line, including the energy degrader and an adaptable 
collimator. The adaptable collimator was set at 5 mm and 10 mm diameter for energy and fluence 
measurement respectively. 
Fig. 2. Proton beam energy measurement set-up. 
Fig. 3. End station of the beam line for radiobiological studies: a mouse immobilization system (a), 
and an automated cell sample holder (b). 
Fig. 4. Fluence-maps measured with the CMOS sensor (left panel) and comparison of the fluence 
lateral profiles between the CMOS sensor, Geant4 and the PSD function. 
Fig. 5. Specific example of a 6 mm xenograft tumor. On the left, PSD calculation of a SOBP 
delivering a total absorbed dose of 1 Gy. On the right panel, the number of protons delivered in a 6 
mm water equivalent depth for each Bragg peak composing the SOBP. 
Fig. 6. Distributions of LETd as a function of depth from 15 MeV to 23 MeV protons (left) and a 
LETd in 6 mm water equivalent depth (example of a xenograft tumor) (right) calculated with Geant4. 
The water equivalent thickness of the petri dish and the energy straggling were taken into account 
for the estimation of LET.  
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